<DOC>
	<DOCNO>NCT00002838</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient refractory chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility toxicity use allogeneic peripheral blood stem cell transplantation intensive , non-myeloablative chemotherapy fludarabine/cyclophosphamide patient advance chronic lymphocytic leukemia . II . Determine engraftment kinetics degree chimerism available strategy . OUTLINE : This nonrandomized , dose-seeking study . Stem cell donor receive G-CSF 4 day prior throughout stem cell harvest . Patients receive intensive chemotherapy fludarabine cyclophosphamide 3 day , patient enter increase dos drug dose allow engraftment determine . Three day intensive chemotherapy , allogeneic stem cell infuse . Responding patient experience bad grade 1 acute graft-vs.-host disease receive additional stem cell infusion 60 120 day . Patients follow monthly 4 month , 6 12 month , yearly 5 year . PROJECTED ACCRUAL : Up 25 patient enter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Advanced chronic lymphocytic leukemia ( Rai stage 3 4 ) least one follow highrisk factor : Beta2 microglobulin 3 great Abnormalities chromosome 17 Other cytogenetic abnormality Refractory fludarabinebased chemotherapy failure achieve complete remission 6 course fludarabinebased regimen HLAidentical sibling donor willing able undergo apheresis harvest GCSFstimulated peripheral blood stem cell PATIENT CHARACTERISTICS : Age : 65 Performance status : Zubrod 0 1 Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Cardiovascular : No symptomatic cardiac disease Pulmonary : No symptomatic pulmonary disease Other : No active uncontrolled infection PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>